@lifeofpoi_'s POI and HRT claims need context

What did @lifeofpoi_ actually say?

Honestly, not much that's fact-checkable. The transcript captured in this video is garbled, appearing to be lyrics or audio bleed rather than any coherent medical claim. What we do know from the caption is that @lifeofpoi_ has primary ovarian insufficiency (POI), was diagnosed at 15, and is using hormone replacement therapy, specifically patches. She's responding to attention from a previous patch-change video. The health content here is biographical, not prescriptive.

That context matters. A young woman sharing her lived experience with early-onset POI on TikTok is doing something genuinely useful for the many people who get this diagnosis and feel completely alone. But because the video is tagged under HRT and early menopause, it's worth using this moment to lay out what the science actually says about HRT in POI.

Does the science back this up?

HRT for POI is not controversial among endocrinologists. It is the standard of care, and the evidence is solid. What often gets lost in social media discussions is why this matters so much more in POI than in typical menopause.

A 2016 guideline from the European Society of Human Reproduction and Embryology (ESHRE) is unambiguous: women with POI should receive hormone therapy until at least the average age of natural menopause, around 51, to protect bone density, cardiovascular function, and cognitive health. The risks of going untreated, including accelerated bone loss and elevated cardiovascular risk, are well-documented. Løkkegaard et al. (2006, BJOG) showed that estrogen deficiency before age 40 significantly increases fracture risk. Shuster et al. (2010, Mayo Clinic Proceedings) linked untreated POI to earlier mortality, a finding that still doesn't get enough public attention.

Transdermal delivery, meaning patches, is generally preferred over oral estrogen in younger women because it avoids first-pass liver metabolism and carries a lower clot risk, according to data from the Women's Health Initiative Memory Study and subsequent analyses.

What did they get wrong (or right)?

There's nothing medically wrong here to correct, because no specific medical claim was made in the captured transcript. What @lifeofpoi_ is doing right is existing publicly with this diagnosis. POI affects roughly 1 in 100 women under 40 (Coulam et al., 1986, Mayo Clinic Proceedings), yet it takes an average of five years to diagnose, partly because clinicians and patients alike don't expect it in young people.

The hashtag community around POI and early menopause on TikTok has measurable value. Patients who feel seen are more likely to advocate for themselves in clinical settings. That said, this space also has a problem with unsupported supplement claims and anti-HRT misinformation bleeding in from general menopause content. Viewers should be careful about distinguishing personal stories from medical guidance, and creators in this space carry some responsibility to flag that line, even briefly.

What should you actually know?

If you have POI or suspect you might, a few things are worth knowing clearly. First, POI is not the same as premature menopause in terms of its hormonal picture. Around 5 to 10 percent of women with POI still have intermittent ovarian function, meaning sporadic periods and even occasional fertility (Nelson, 2009, New England Journal of Medicine). This is why the condition used to be called premature ovarian failure, a term now largely retired because it's both inaccurate and stigmatizing.

Second, HRT for POI is not the same risk conversation as HRT for a 55-year-old starting therapy a decade after menopause. The risk profile is different. The benefit profile is different. If you've been scared off HRT by headlines about breast cancer risk in older postmenopausal women, know that those numbers don't directly apply to someone replacing hormones they should naturally have at 25.

Third, testosterone is sometimes used alongside estrogen in POI management for libido and energy, though evidence specifically in POI is thinner than in typical menopause. Davis et al. (2019, The Lancet Diabetes and Endocrinology) reviewed testosterone use in women broadly, finding benefit for hypoactive sexual desire disorder, but dosing guidance for younger women with POI specifically remains an active area of research.

The bottom line

This video is a personal story, not a medical tutorial. The creator isn't making claims that need correcting. But the 332,000 people who watched it deserve to know that the science behind HRT for POI is strong, that patches are a reasonable delivery method with real pharmacological rationale, and that getting a diagnosis this young is more common than most people think. If any of this resonates with your situation, talk to a clinician who specializes in reproductive endocrinology, not just a GP who may not have seen POI in years.